Harmony Biosciences Says New Data Supports Neurology Pipeline
Harmony Biosciences stock jumped after record Q2 revenue, an earnings beat, strong WAKIX sales and updated analyst price targets.
Harmony Biosciences made more money than expected and their main medicine WAKIX is selling really well. When a company does better than people thought, investors get excited and that can be a sign the business is growing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.